Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C

Digestive and Liver Disease

Volumn 44, Issue 1, 2012, Pages 86-87

  Maratea, Dario ^a   Messori, Andrea ^a   Fadda, Valeria ^a  

^a ESTAV   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG RESPONSE; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; LETTER; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; FORECASTING; HEALTH EXPENDITURES; HEPATITIS C, CHRONIC; HUMANS; ITALY; PROTEASE INHIBITORS;

EID: 83855160870     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.08.016     Document Type: Letter

References (5)

1. Messori A., Del Santo F., Maratea D. First-line treatments for hepatitis C. Aliment Pharmacol Ther 2011, 33:1383-1385.
2. Northup PG, Al-Osaimi AM, Caldwell SH, Argo CK. Cost effectiveness of STAT-C agents in treating genotype 1 chronic hepatitis C (Abstract 782). The 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, 30 October-3 November 2009.
3. Marcellin P., Chousterman M., Fontanges T., et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011, 31:516-524.
4. Mazzeo C., Azzaroli F., Giovanelli S., et al. Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut 2003, 52:1030-1034.
5. Maratea D. Economic consequences of approval extensions: the case of rituximab (published 26 May 2011). eBMJ, available at http://www.bmj.com/content/338/bmj.b67.extract/reply%23bmj_el_261164.